A C A D E MY
INTERNATIONAL ACADEMY OF GMP TRAINING (IAGT)
                                                          GMP REVIEW
              AL
TE R N A TI O N
                                   OF
                                   G MP T RAIN                                                                      March 2004
                                                                                                                      Issue III
  IN
                  E               IN
                      TH      G
        This month’s GMP News covers:                                  2004 and will incorporate:
       n New and revised EU Guidelines                                  n The Certificate of Suitability System of the European
       n The introduction of bar coding on medicines in the USA         Pharmacopoeia
       n Developments with the Mutual Recognition Agreement             n The Common Technical Document format for market-
       between the EU and Japan.                                        ing authorisation applications. (IMPs)
                                                                       To see this guideline click on:
                                                                         EDMF Guideline
        DEVELOPMENTS IN GMP AND
        REGULATORY REQUIREMENTS                                         II. UNITED STATES OF AMERICA
                                                                        II. A. FDA
                                                                       Bar Code Label Requirement for Human Drug
        I. EUROPE                                                      Products and Biological Products - 21 CFR Parts
                                                                       201, 606, and 610 (Final Rule)
    I.A. Further revision of the Compilation of EU                     The FDA is to issue a final rule to introduce a requirement
   Procedures on Inspections and the Exchange of                       for linear bar codes to appear on most medicines sold in
   Information                                                         the USA.. The reason behind this is to reduce the number
   The European Medicines Agency EMEA has issued the sec-              of medication errors.
   ond revision of the Compilation of Procedures Used by the           Products will have to be brought into compliance over the
   GMP Inspectorates of the EU Member States. This follows             next 2 years:
   the last revision in December 2003.
                                                                        USA bar code requirements
   The additions to this version are:
    n A revised section on the training and qualifications of
    GMP inspectors
                                                                        INTERNATIONAL
    n A new annex on the conduct of inspections of the man-
    ufacture of investigational medicinal products (IMPs)
   These changes appear to result from harmonisation acti-              DEVELOPMENTS
   vities within the EU and the implementation of the Clinical
   Trials Directive on May 1st 2004.
   You can access this document by clicking on:
                                                                        II. MRA
        Revised Compilation of Inspection Procedures*
                                                                        II.A. Mutual Recognition Agreements (EC-
    I.B. Note for Guidance on Plastic Primary                          Japan
   Packaging Materials                                                 The EC and Japan have re-confirmed the equivalence and
   A revised version of this Guideline was issued recently for         implementation of the GMP requirements in accordance
   consultation. The closing date for comments (to the EMEA)           with the EC-Japan MRA.
   is August 31st 2004.
                                                                       Agreement was also reached on the procedures required
   If you are interested you can see a copy of the draft NFG           for the operational phase of this Sectoral Annex to the
   by clicking on:                                                     MRA.
     Draft Guideline on Plastic Primary Packaging Materials
                                                                       A public statement on the MRA can be seen by clicking
     I. C. Guideline on Stability Testing for Active                   on:
   Substances and Medicinal Products (Marketed                           EC-Japan MRA Statement
   in the EU) that are Manufactured in Climatic
                                                                       The results of this Agreement should be to make life easi-
   Zones III and IV.                                                   er for companies in the EU that export medicines to or
   Draft guidance has been issued extending the existing sta-          import medicines from Japan. You can find more informa-
   bility guideline to cover products made in hot and dry or           tion about this and other MRAs on the EMEA’s website at
   hot and humid climatic zones that are to be marketed in             the address given on page 2.
   the EU. The closing date for comments be sent (to the
   EMEA) is the end of August 2004.
   To see a copy of this document click on:
     Draft Guideline on Stability Testing                               FOR ALL YOUR QUERIES, PLEASE CONTACT
     I.D. Guideline on the Active Substance Master                      IAGT TUTOR STEVE FAIRCHILD ON;
   File Procedure (European Drug Master File -                          steve.fairchild@iagtgroup.com
   EDMF)
   An updated version of this guidance document has been                To subscribe to the IAGT GMP Review, please
   published. This will come into operation on August 31st              send an e-mail to:
                                                                        subscribe@iagtgroup.com
                                                             www.iagtgroup.com
                       A C A D E MY              INTERNATIONAL ACADEMY OF GMP TRAINING (IAGT)
                                                    GMP REVIEW
              AL
TE R N A TI O N
                                   OF
                                   G MP T RAIN                                                      (cont’d)
  IN
                  E               IN
                      TH      G
          USEFUL ADDRESSES / LINKS                                          FDA CBER Guidelines/Points to Consider:
                                                                            http://www.fda.gov/cber/guidelines.htm
  Please note that some of the addresses include underscored spaces,
  which may be difficult to see as they appear in written documents.
  You will also need to use Adobe Acrobat Reader, which can be down-        FDA Human Drugs GMP Notes:
  loaded from: http://www.adobe.com/products/acrobat                        http://www.fda.gov/cder/dmpq/cgmpnotes.htm
   British Pharmacopoeia (BP):                                              Japanese Ministry of Health, Labor & Welfare
   http://www.pharmacopoeia.org.uk                                          (MHW):
                                                                            http://www.mhlw.go.jp/english
   Canadian HPFB Inspectorate:
   h t t p : / / w w w . h c - s c . g c . c a / h p f b -
                                                                            International Conference on Harmonisation
   dgpsa/inspectorate/index_e.html
                                                                            (ICH):
                                                                            http://www.ich.org/UrlGrpServer.jser?@_ID=276&@_TEM
   European Agency for the                                Evaluation   of   PLATE=254
   Medicinal Products (EMEA):
   http://www.emea.eu.int
                                                                            International Society           of   Pharmaceutical
                                                                            Engineers (ISPE):
   European Agency for the Evaluation                                  of   http://www.ispe.org
   Medicinal Products Inspections Sector:
   http://www.emea.eu.int/Inspections/index.html
                                                                            International Pharmaceutical Federation (FIP):
                                                                            http://www.fip.nl
   European Chemical Industry Council – Active
   Pharmaceutical Ingredients Sector                                        International         Pharmaceutical       Excipients
   (CEFIC/APIC):                                                            Council (IPEC):
   http://apic.cefic.org
                                                                            http://www.ipec.org
   European Guide to GMP:
                                                                            The UK Medicines and Health Care Products
   http://pharmacos.eudra.org/F2/eudralex/vol-4/home.htm
                                                                            Regulatory Agency (MHRA):
                                                                            http://www.mhra.gov.uk
   European Guide to GMP – updates etc:
   http://pharmacos.eudra.org/F2/pharmacos/gmp_doc.htm
                                                                            The Irish Medicines Board:
                                                                            http://www.imb.ie
   European Compilation of Procedures for GMP
   Inspections:
                                                                            Mutual Recognition Agreements (MRA’s):
   http://www.emea.eu.int/Inspections/docs/335103en.pdf
                                                                            http://www.emea.eu.int/Inspections/MRA.html
   European    Federation   of   Pharmaceutical
                                                                            The Pharmaceutical Quality Group (PQG):
   Industries and Federations (EFPIA):                                      http://www.pqg.org/welcome.asp
   http://www.efpia.org
                                                                            Pharmaceutical and Research Manufacturers of
   European Guidelines on Quality, Safety &                                 America (PhRMA):
   Efficacy:                                                                http://www.phrma.org
   http://www.emea.eu.int/sitemap.htm
                                                                            Pan European Regulatory Forum (PERF III)
   European Pharmacopoeia (Ph Eur):                                         http://perf.eudra.org/perf3/perf1.html#
   http://www.pheur.org
                                                                            Pharmaceutical  Inspection    Co-operation
   FDA “Portal” - providing access to the different                         Scheme (PIC/S)-GMP Guide & Basic Standards:
   parts of their website:                                                  http://www.picscheme.org/index.htm
   http://www.fda.gov/oc/industry/default.htm
                                                                            UK Official Documents Including the “Orange
   FDA GMP Regulations (CFR21):                                             Guide” and Medicines Legislation:
   http://www.access.gpo.gov/nara/cfr/waisidx_01/21cfr211                   http://www.tso.co.uk/bookshop/bookstore.asp
   _01.html
                                                                            United States Pharmacopoeia (USP):
   FDA Inspections Operation Manual:                                        http://www.usp.org
   http://www.fda.gov/ora/inspect_ref/iom/iomtc.html
                                                                            World Health Organisation GMP Information
   FDA Inspection Guides
                                                                            (WHO):
   http://www.fda.gov/ora/inspect_ref/igs/iglist.html
                                                                            http://www.who.int/medicines/organization/qsm/activities
                                                                            /qualityassurance/gmp/gmpcover.html
                                                                   © IAGT,2004